NCT00258830View on ClinicalTrials.gov

Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

February 28, 2006

Study Completion Date

March 31, 2007

Conditions
Influenza
Interventions
BIOLOGICAL

Fluzone®: Influenza Virus Vaccine

0.5 mL, Intramuscular

BIOLOGICAL

Fluzone®: Influenza Virus Vaccine

0.5 mL, Intramuscular

Trial Locations (1)

23507

Norfolk

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00258830 - Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine | Biotech Hunter | Biotech Hunter